Drugging the Poor

Photo: Wikimedia Commons

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.

Poor children are more likely to occupy prisons and live near hazardous waste facilities than their middle-class peers—and now, The New York Times reports, children covered by Medicaid are prescribed antipsychotics at a rate four times higher than children whose parents have private insurance. Even more troubling: The FDA has approved many of these drugs to treat only schizophrenia and bipolar disorders, but doctors have been prescribing them to poor kids who suffer from more common conditions like attention deficit hyperactivity disorder (ADHD), aggression, and “persistant defiance,” which are often diagnosed by family doctors instead of psychiatrists.

The reason for this disparity? Medicaid often pays much less for family counseling and psychotherapy than private insurers do, and families living below the poverty line don’t have time to attend counseling and therapy sessions anyway, the article posits. Poverty itself can exacerbate the many problems the kids are receiving medication for:

Experts generally agree that some characteristics of the Medicaid population may contribute to psychological problems or psychiatric disorders. They include the stresses of poverty, single-parent homes, poorer schools, lack of access to preventive care and the fact that the Medicaid rolls include many adults who are themselves mentally ill.

But drugging the poor doesn’t come cheap:

Even though the drugs are typically cheaper than long-term therapy, they are the single biggest drug expenditure for Medicaid, costing the program $7.9 billion in 2006, the most recent year for which the data is available.

Since a large portion of state Medicaid spending is financed by grants from the federal government, pharmaceutical companies receiving Medicaid revenues benefit from overmedicating the poor, and so does the government, which receives a portion of the pharmaceutical companies’ revenues from sales to Medicaid patients. Something to think about, given the fact that Congress is currently hammering out health care legislation that could increase the amount of people on Medicaid by 15 million.


Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend